Advertisement

Bioprospecting for Pharmaceuticals: An Overview and Vision for Future Access and Benefit Sharing

  • Danielle Cicka
  • Cassandra QuaveEmail author
Chapter

Abstract

The vast therapeutic benefits of plants have been recognized for centuries, yet there is still a large, untapped potential for commercial medicine production. In fact, several of the most important pharmaceuticals have been based on compounds found in natural products. Bioprospecting encompasses this search for the commercial potential of medicinal natural products. The search for these drugs from nature contains unique opportunities and challenges. Within the confines of the US pharmaceutical industry, the process of drug discovery must encompass the well-being of the countries and people from which the botanical information and specimen have been obtained, while conserving plant diversity and maintaining a competitive advantage in the industry. Nature contains incredibly unique chemical compounds of unparalleled diversity, ripe for new classes of therapeutics if care can be taken to ensure the benefit for local communities, the environment, and scientists. Therefore, this chapter describes triumphs and struggles of bioprospecting and framework for the future.

Keywords

Drug discovery Regulatory environment Intellectual property 

References

  1. Aratikatla EK, Valkute TR, Puri SK, Srivastava K, Bhattacharya AK (2017) Norepinephrine alkaloids as antiplasmodial agents: synthesis of syncarpamide and insight into the structure-activity relationships of its analogues as antiplasmodial agents. Eur J Med Chem 138:1089–1105.  https://doi.org/10.1016/j.ejmech.2017.07.052CrossRefPubMedGoogle Scholar
  2. Atanasov AG et al (2015) Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv 33:1582–1614.  https://doi.org/10.1016/j.biotechadv.2015.08.001CrossRefPubMedPubMedCentralGoogle Scholar
  3. Benz BF, Cevallos J, Santana F, Rosales J, Graf S (2000) Losing knowledge about plant use in the Sierra de Manantlan biosphere reserve, Mexico. Econ Bot 54:183–191CrossRefGoogle Scholar
  4. BMS (2011) TAXOL (paclitaxel) injectionGoogle Scholar
  5. Camp D, Davis RA, Campitelli M, Ebdon J, Quinn RJ (2012) Drug-like properties: guiding principles for the design of natural product libraries. J Nat Prod 75:72–81.  https://doi.org/10.1021/np200687vCrossRefPubMedGoogle Scholar
  6. CBD (2011) Nagoya protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization to the convention on biological diversity. United Nations, MontrealGoogle Scholar
  7. CBD (2017) Parties to the Nagoya protocol. Convention on Biological Diversity. https://www.cbd.int/abs/nagoya-protocol/signatories/default.shtml
  8. CITES (n.d.) Convention on international trade in endangered species of wild fauna and flora appendices I, II, IIIGoogle Scholar
  9. Danley V (2011) Biopiracy in the Brazilian Amazon: learning from International and comparative law successes and shortcomings to help promote biodiversity conservation in Brazil. Florida A & M Univ Law Rev 7:291Google Scholar
  10. DeNicola GM et al (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475:106–109.  https://doi.org/10.1038/nature10189CrossRefPubMedPubMedCentralGoogle Scholar
  11. DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47:20–33.  https://doi.org/10.1016/j.jhealeco.2016.01.012CrossRefPubMedGoogle Scholar
  12. Elvin-Lewis M (2007) Evolving concepts related to achieving benefit sharing for custodians of traditional knowledge. Afr J Tradit Complement Altern Med 4:443–468PubMedGoogle Scholar
  13. Elvin-Lewis M (2011) Dereplications can amplify the extent and worth of traditional pharmacopeias. Afr J Tradit Complement Altern Med 8:13–26.  https://doi.org/10.4314/ajtcam.v8i5S.12CrossRefPubMedPubMedCentralGoogle Scholar
  14. ETC (2001) US Government’s $2.5 million biopiracy project in Mexico cancelled. ETC Group. http://www.etcgroup.org/fr/node/232
  15. FDA (1999) Title, 21 C.F.R. S 314.108Google Scholar
  16. Flamini G, Catalano S, Caponi C, Panizzi L, Morelli I (2002) Three anthrones from Rubus ulmifolius. Phytochemistry 59:873–876CrossRefGoogle Scholar
  17. Greaves T (1994) Intellectual property rights for indigenous peoples: a sourcebook. Society for Applied Anthropology, OklahomaGoogle Scholar
  18. Guenard D, Gueritte-Voegelein F, Potier P (1993) Taxol and taxotere: discovery, chemistry, and structure-activity relationships. Acc Chem Res 26:160–167.  https://doi.org/10.1021/ar00028a005CrossRefGoogle Scholar
  19. Guerin-McManus M, Nnadozie KC, Laird SA (2002) The use of conservation trust funds for sharing financial benefits in bioprospecting projects. Adv Phytomed 1:211–240CrossRefGoogle Scholar
  20. Harvey AL (2008) Natural products in drug discovery. Drug Discov Today 13:894–901.  https://doi.org/10.1016/j.drudis.2008.07.004CrossRefPubMedGoogle Scholar
  21. Hayden C (2003) When nature goes public: the making and unmaking of bioprospecting in Mexico. Princeton University Press, PrincetonGoogle Scholar
  22. Heinrich M (2001) Journal of Ethnopharmacology: an interdisciplinary journal devoted to indigenous drugs. J Ethnopharmacol 76:137–138.  https://doi.org/10.1016/S0378-8741(01)00255-0CrossRefPubMedGoogle Scholar
  23. Hirshfeld AH (2014) 2014 Procedure for subject matter eligibility analysis of claims reciting or involving laws of nature/natural principles, natural phenomena, and/or natural products. Commissioner for Patents, Alexandria, VAGoogle Scholar
  24. Holmes FA et al (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797–1805.  https://doi.org/10.1093/jnci/83.24.1797CrossRefPubMedGoogle Scholar
  25. Hunter P (2008) Harnessing nature’s wisdom. Turning to nature for inspiration and avoiding her follies. EMBO Rep 9:838–840.  https://doi.org/10.1038/embor.2008.160CrossRefPubMedPubMedCentralGoogle Scholar
  26. ISE (2006) International Society of Ethnobiology Code of Ethics (with 2008 additions). http://www.ethnobiology.net/what-we-do/core-programs/ise-ethics-program/code-of-ethics/code-in-english/
  27. King S (1994) Establishing reciprocity: biodiversity, conservation and new models for cooperation between forest-dwelling peoples and the pharmaceutical industry intellectual property rights for indigenous peoples: a source book thomas greaves. Society for Applied Anthropology, OklahomaGoogle Scholar
  28. Krauss M (1992) The world’s languages in crisis. Language 68:4–10CrossRefGoogle Scholar
  29. Kursar TA (2011) What are the implications of the Nagoya protocol for research on biodiversity? Bioscience 61:256–257.  https://doi.org/10.1525/bio.2011.61.4.2CrossRefGoogle Scholar
  30. Lee YK, Bang HJ, Oh JB, Whang WK (2017) Bioassay-guided isolated compounds from Morinda officinalis inhibit Alzheimer’s disease pathologies. Molecules 22.  https://doi.org/10.3390/molecules22101638
  31. Malik S, Cusidó RM, Mirjalili MH, Moyano E, Palazón J, Bonfill M (2011) Production of the anticancer drug taxol in Taxus baccata suspension cultures: a review Process. Biochemistry 46:23–34.  https://doi.org/10.1016/j.procbio.2010.09.004CrossRefGoogle Scholar
  32. McGuire WP, Rowinsky EK, Rosenshein NB et al (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273–279.  https://doi.org/10.7326/0003-4819-111-4-273CrossRefPubMedGoogle Scholar
  33. Medaglia JC, Silva CL (2007) Addressing the problems of access: protecting sources, while giving users certainty vol 1. IUCN, GlandCrossRefGoogle Scholar
  34. NCCIH (2015) Network pharmacology and natural products. https://nih.webex.com/nih/ldr.php?RCID=fdde5ac7b1aa12dbe78cda06f475f039
  35. Ningthoujam SS, Talukdar AD, Potsangbam KS, Choudhury MD (2012) Challenges in developing medicinal plant databases for sharing ethnopharmacological knowledge. J Ethnopharmacol 141:9–32.  https://doi.org/10.1016/j.jep.2012.02.042CrossRefPubMedGoogle Scholar
  36. Quezada F (2007) Status and potential of commercial bioprospecting activities in Latin America and the Caribbean. United Nations University Press, TokyoGoogle Scholar
  37. RAFI (1993) Bio-piracy: the story of natural coloured cottons of the Americas RAFI CommuniqueGoogle Scholar
  38. Ramirez CR (2007) Ethnobotany and the loss of traditional knowledge in the 21st century 2007 5:3 doi: https://doi.org/10.17348/era.5.0.245-247CrossRefGoogle Scholar
  39. RBGK (2017) The state of the World’s plants report 2017. Royal Botanic Gardens at Kew. https://stateoftheworldsplants.com/
  40. Reyes-García V (2010) The relevance of traditional knowledge systems for ethnopharmacological research: theoretical and methodological contributions. J Ethnobiol Ethnomed 6:32.  https://doi.org/10.1186/1746-4269-6-32CrossRefPubMedPubMedCentralGoogle Scholar
  41. Reyes-García V et al (2013) Evidence of traditional knowledge loss among a contemporary indigenous society. Evol Hum Behav 34:249–257.  https://doi.org/10.1016/j.evolhumbehav.2013.03.002CrossRefPubMedCentralGoogle Scholar
  42. Richerzhagen C (2011) Effective governance of access and benefit-sharing under the convention on biological diversity. Biodivers Conserv 20:2243–2261CrossRefGoogle Scholar
  43. Robinson DF (2010) Confronting biopiracy: challenges, cases and international databases. Earthscan, LondonCrossRefGoogle Scholar
  44. Robles AJ et al (2017) Structure-activity relationships of new natural product-based diaryloxazoles with selective activity against androgen receptor-positive breast cancer cells. J Med Chem.  https://doi.org/10.1021/acs.jmedchem.7b01228CrossRefGoogle Scholar
  45. Rocha DMAL (2003) Riqueza ameaçadaGoogle Scholar
  46. Rose J, Quave CL, Islam G (2012) The four-sided triangle of ethics in bioprospecting: pharmaceutical business, international politics, socio-environmental responsibility and the importance of local stakeholders. Ethnobiology and Conservation 1Google Scholar
  47. Rosenthal JP (1997) Equitable sharing of biodiversity benefits: agreements on genetic resources. In: Investing in biological diversity: proceedings of the cairns conference, 1997. pp 253–274Google Scholar
  48. Sampath PG (2005) Regulating bioprospecting: institutions for drug research, access and benefit-sharing. United Nations University Press, TokyoGoogle Scholar
  49. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665–667CrossRefGoogle Scholar
  50. Silva FÁ, Espindola LS (2011) Access legislation on genetic resources patrimony and traditional knowledge. Rev Bras 21Google Scholar
  51. Stierle A, Strobel G, Stierle D (1993) Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew. Science 260:214–216CrossRefGoogle Scholar
  52. Suffness M, Douros J (1982) Current status of the NCI plant and animal product program. J Nat Prod 45:1–14.  https://doi.org/10.1021/np50019a001CrossRefPubMedGoogle Scholar
  53. UN (1992) Convention on biological diversity. Rio de JaneiroGoogle Scholar
  54. USPAT (2015) General information concerning patents. United States Patent and Trademark OfficeGoogle Scholar
  55. van Rozendaal ELM, Lelyveld GP, van Beek TA (2000) Screening of the needles of different yew species and cultivars for paclitaxel and related taxoids. Phytochemistry 53:383–389.  https://doi.org/10.1016/S0031-9422(99)00094-1CrossRefPubMedGoogle Scholar
  56. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327.  https://doi.org/10.1021/ja00738a045CrossRefPubMedGoogle Scholar
  57. WHO (2002) World health organization traditional medicine strategy 2002–2005. World Health Organization, GenevaGoogle Scholar
  58. WHO (2003) World Health Organization guidelines on good agricultural and collection practices (GACP) for medicinal plants. World Health Organization, GenevaGoogle Scholar
  59. WHO (2016) Overview of malaria treatment. World Health Organization, Geneva. http://www.who.int/malaria/areas/treatment/overview/en/Google Scholar
  60. WHO (2017) WHO model list of essential medicine, 20th edn. World Health Organization, GenevaGoogle Scholar
  61. Wong AY-T, Chen AW-K (2014) Myriad and its implications for patent protection of isolated natural products in the United States. Chin Med 9CrossRefGoogle Scholar
  62. Worthen DB (2004) American pharmaceutical patents from a historical perspective. Int J Pharmaceut CompoundGoogle Scholar
  63. WTO (1995) Trade-related aspects of intellectual property rightsGoogle Scholar
  64. Wynberg R, Schroeder D, Chennells R (2009) Indigenous peoples, consent and benefit sharing: lessons from the san-hoodia case. Springer, BerlinCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Emory UniversityAtlantaUSA

Personalised recommendations